tbuckley/cabot-search huggingface dataset:
Are the criteria indicating patients to be “medically inoperable” that are used in clinical trials on stereotactic body radiotherapy appropriate for patients with early stage non-small cell lung cancer?
Authors: K. Takamochi, A. Hattori, T. Maeyashiki, T. Matsunaga, T. Banno, S. Oh, K. Suzuki
Journal: Annals of Oncology (2016)
Oxygen Supplementation Among Patients in the Intensive Care Unit
Authors: Angelique M. E. Spoelstra-de Man, Heleen M. Oudemans-van Straaten, Armand R. J. Girbes
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Authors: A. Lamarca, D.M. Pritchard, T. Westwood, G. Papaxoinis, S. Vinjamuri, J.W. Valle, P. Manoharan, W. Mansoor
Journal: Annals of Oncology (2016)
RTHP-39. SURVIVAL OUTCOME OF LONG-TERM RESPONDERS TO FRACTIONATED VERSUS SINGLE-DOSE STEREOTACTIC RADIOSURGERY (SRS)
Authors: Winston Vuong, Leanne Goldstein, Eric Radany, Mike Chen, Behnam Badie, Savita Dandapani
Journal: Neuro-Oncology (2016)

Treatment of brain metastases with fractionated stereotactic radiosurgery (F-SRS) is predicated on intent to reduce radiation toxicity without compromising local control. In patients with large brain metastases, F-SRS has been suggested to have improved local control compared to single-fraction stereotactic radiosurgery (S-SRS) with acceptable toxicity. The differences, though, between patients who undergo S-SRS and F-SRS that survive well beyond the one-year time frame are still unclear. Here we present a retrospective review of brain-metastatic lung and breast cancer patients that survived at least one year from initial SRS. A total of 91 patients, 58 lung- and 33 breast-primary, were treated between September 2006 and October 2014 with a median overall survival from initial SRS (SRS-mOS) of 24.9 months (range, 12.1-84.9 months). 203 lesions were irradiated in 86 patients (range, 1 to 9). The S-SRS group included 34 patients (26 lung, 8 breast) and the F-SRS group had 57 patients (32 lung, 25 breast). The S-SRS group received total doses ranging from 15-20 Gy (median, 17 Gy) and the F-SRS group received total doses ranging from 20-25 Gy in 3-5 fractions (median, 21 Gy). The median age was 59.6 yo (range, 31.2-85.1 yo). Kaplan-Meier analyses revealed no significant difference between single-dose and fractionation (S-SRS, 28.3 mo; and F-SRS,31.8 mo; p=0.5735) even when adjusted for primary cancer site. No differences were seen between primary site (p=0.3284) or 1-4 vs. 5 or more brain metastases (p=0.8364). The similarity in survival between S-SRS and F-SRS suggests that fractionation may be used without compromising survival, although it remains to be seen how other prognostic factors influence outcomes in this cohort.
Dose-reduction gemcitabine and S1 combination therapy in over 70 years old patients with unresectable pancreatic cancer
Authors: Shinya Ooka, Naoaki Dan, Osamu Noguchi, Toshihiko Nouchi, Yoshinori Sakai, Takahiro Kawamura, Hiroyuki Sakashita, Makoto Tomita, Satoshi Miyake, Mamoru Watanabe
Journal: Annals of Oncology (2016)
Imatinib Induced Re-Activation of FoxO3 Transcription Factor in CML Is Responsible for the Induction of a Quiescent Status of CD34 Leukaemic Progenitor Cells.
Authors: Daniela Cilloni, Cristina Panuzzo, Francesca Messa, Francesca Arruga, Enrico Bracco, Roberto Bernardoni, Sonia Carturan, Marisa Pautasso, Emanuela Messa, Alessandro Morotti, Monica Pradotto, Ilaria Iacobucci, Thea Kalebic, Giovanni Martinelli, Giuseppe Saglio
Journal: Blood (2008)
LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Authors: A. Horiike, K. Yoh, T. Seto, M. Satouchi, M. Nishio, N. Yamamoto, H. Murakami, N. Nogami, S. Nomura, A. Sato, A. Ohtsu, K. Goto
Journal: Annals of Oncology (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).
Authors: George R. Buchanan, Lisa Bomgaars, James B. Bussel, Diane J. Nugent, David J. Gnarra, Victor S Blanchette, Kun Nie, Melissa Eisen, Dietmar Berger
Journal: Blood (2009)
Most cases of cerebral palsy are associated with antenatal events
Authors: Christoph Lees
Journal: BMJ (2017)

Nelson and colleagues call for an impartial expert task force to consider whether electronic fetal monitoring in labour reduces the risk of cerebral palsy.1 But that isn’t really the issue—nor has it been for at least three decades. Cardiotocography detects, through fetal heart rate recording, hypoxia …
Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
Authors: J. Huang, Y. Liu, S. Dai, P. Lu, Y. Ba, L. Wu, Y. Bai, S. Zhang, J. Feng, Y. Cheng, J. Li, L. Wen, X. Yuan, C. Ma, Q. Fan, X. Wang, B. Xu
Journal: Annals of Oncology (2016)
A Novel Mutation 774del4 in IFNGR1, Which Produces Truncated Form of Interferon γ Receptor 1, Causes a Dominant-Negative Effect on Interferon γ Signal Transduction.
Authors: Satoshi Okada, Nobutsune Ishikawa, Kenichirou Shirao, Hiroshi Kawaguchi, Miyuki Tsumura, Yoshinori Ohno, Shin’ichiro Yasunaga, Motoaki Ohtsubo, Yoshihiro Takihara, Masao Kobayashi
Journal: Blood (2006)
Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol 2017;72:289–92. Do the Data Violate Kaplan-Meier Assumptions?
Authors: Giorgio Gandaglia, Nicola Fossati, Francesco Montorsi, Alberto Briganti
Journal: European Urology (2017)
RARE-38. NOVEL TARGETS IN EPENDYMAL TUMORS
Authors: Nader Sanai, Joanne Xiu, Lyndon Kim, Santosh Kesari, Shouhao Zhou, John de Groot, Amy Heimberger
Journal: Neuro-Oncology (2016)

Despite surgery and radiation for ependymomas, dissemination and recurrence occur. The role of chemotherapy is not well-defined. Alternative targeted approaches are desperately needed. Ependymal tumors (total, n=47; cranial, n=30; spinal, n=17; grade-I, n=8; grade-II, n=11; grade-III, n=23) were profiled by Caris Life Sciences using immunohistochemistry, next-generation sequencing, and in-situ hybridization. The median age was 34, spanning 3-79 years. Cranial tumors occurred in younger patients than spinal tumors (median age 29.5 vs. 47; p=0.018). There was a trend for a higher incidence of spinal tumors in males, at 65% vs 37% in cranial tumors (p=0.07). While 3%, 23%, and 63% of cranial tumors were of grades-I, -II, and -III, respectively, spinal tumors were of lower grade, with 41%, 24%, and 24% being of grades-I, -II, and -III. The DNA excision repair protein ERCC1, which correlates with cisplatin resistance, is frequently expressed in grade-I (80%, 4/5) tumors but is absent in 57% of grade-II (4/7), and grade-III (8/14). ERCC1 expression is more frequent in spinal tumors (67%; 6/9) than in cranial (42%, 8/19). ­MGMT-promoter-methylation was seen in 14% of tumors and over-expression in 17%. Frequently overexpressed targets included PTEN (80%, 36/45), BCRP (75%, 6/8), TOPO1 (62%; 26/42), EGFR (62%, 8/13), TUBB3 (52%; 12/23), and RRM1 (49%; 17/35). Adult were more likely to have PTEN over-expression than pediatric(31/35 vs 5/10; p=0.017) or RRM1 overexpression (17/30 vs 0/5, p=0.045). TOPO1 expression decreased with grade (I=86%, II=73%, III=55%; p=0.015) while thymidylate synthase expression increased with grade (I=13%, II=18%, III=66%; p=0.058). Among 23 tumors sequenced, PTEN K267fs was seen in one grade-III cranial tumor. An ALK translocation was identified in one grade-III ependymoma. If predicated on tumor expression, our data suggest that therapeutics directed toward ERCC1, ALK, PTEN, TOPO1, EGFR, TUBB3, and RRM1 could be considered for conventional treatment-refractory ependymal tumor patients.
A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)
Authors: Y. Nishioka, K. Hasegawa, A. Saiura, M. Oba, J. Yamamoto, Y. Nomura, T. Takayama, Y. Hashiguchi, M. Shibasaki, H. Sakamoto, S. Yamagata, N. Aoyanagi, H. Kaneko, H. Koyama, S. Miyagawa, Y. Mise, E. Shinozaki, S. Yoshida, H. Nozawa, N. Kokudo
Journal: Annals of Oncology (2018)
EXTH-34. EPIGENOMIC TREATMENT FOR IDH WILD-TYPE GRADE III GLIOMA, TARGETING DYSREGULATION OF EZH2-H3K27me3
Authors: Fumiharu Ohka, Shouichi Deguchi, Hiromichi Suzuki, Kosuke Aoki, Keisuke Katsushima, Keiko Shinjo, Toshihiko Wakabayashi, Yutaka Kondo, Atsushi Natsume
Journal: Neuro-Oncology (2016)

IDH gene mutation characterizes approximately 80% of grade II and III gliomas and defines a subtype with favorable prognosis, especially in grade III gliomas. Mutant IDH is known to contribute to glioma initiation, inducing Glioma-CpG Islands Methylator Phenotype (G-CIMP). By contrasts, the mechanism of IDH wild-type grade III glioma formation is not well-understood, although this type glioma reveals as dismal prognosis as glioblastoma (GBM) does. We found that spontaneously developed gliomas in mouse model with Tp53 and Nf1 loss and human IDH wild-type grade III glioma share many abnormalities in common. One of the major alterations was that, expression level of EZH2, a methyltransferase of histone H3K27, is significantly upregulated in IDH wild-type grade III glioma samples, compared with IDH mutated gliomas. Our mouse model enables us to trace mutant cells with labeling of Green Fluorescent Protein (GFP) during tumor formation. Intriguingly, EZH2 is upregulated from an early stage of glioma-genesis in mouse model. Chromatin Immuno-precipitation (ChIP) analysis reveals sequential accumulation of genes with H3K27me3 modifications during tumor formation, aberrantly (1,066, 1,574 and 2,561 genes, in a normal astrocyte, mutant cells in post-natal 8 days and 120 days respectively). Large number of neural differentiation associated genes are downregulated, via aberrant H3K27me3 marks. Knock-out of EZH2 reactivates these H3K27me3 targets, together with significant reduction of tumor size (P<0.05). MRI imaging revealed that an oral administration of an inhibitor of EZH2, inhibited tumor growth, significantly (P=0.01). Our data indicates that IDH wild-type grade III glioma depends on dysregulation of EZH2-H3K27me3, suggesting that this type glioma might behave a hyper-methylator phenotype of histone H3K27. For lethal IDH wild-type grade III glioma, an inhibition of EZH2 might be a promising therapy.
Early responses to enzalutamide in AR-V7 positive first line metastatic castration-resistant prostate cancer (mCRPC). A prospective SOGUG clinical trial: The PREMIERE study
Authors: E. Grande, M.P. Fernández Pérez, A. Font, S. Vazquez, B. Mellado, O. Fernandez Calvo, M.J. Méndez Vidal, M.A. Climent, A. González del Alba, E. Gallardo, A. Rodríguez Sánchez, C. Santander, M.I. Sáez, I. Duran, J. Puente, T. Alonso Gordoa, J. Tudela, A. Martínez, D. Castellano, E. González Billalabeitia
Journal: Annals of Oncology (2016)
P07.05 Intracellular pH measured by 31P MR-Spectroscopy predicts site of progression in recurrent glioblastoma under antiangiogenic therapy with bevacizumab
Authors: K. J. Wenger-Alakmeh, U. Pilatus, E. Hattingen, O. R. Bähr
Journal: Neuro-Oncology (2016)

1/23, tuberculosis 1/23), and a histiocytosis was found in 1/23].MRI findings revealed 15 patients with diffuse lesions vs 8 focal lesions respectively and 21 patients with enhancing lesions vs 2 patients with nonenhancing brainstem lesions.CONCLUSION: Despite its retrospective nature, our study underlines the risk of misdiagnosis and therapeutic mistakes in the evaluation of infiltrating mass suggesting brainstem glioma.It illustrates the need to promote a more systematic "check-list" based approach of brainstem lesions, including biopsies when needed, as recently shown in the pediatric population. P07.
UV1 - A peptide-based, therapeutic cancer vaccine targeting the reverse transcriptase subunit of human telomerase (hTERT)
Authors: E.M. Inderberg, W. Lilleby, T.K. Guren, P.F. Brunsvig, K. Lislerud, A. Tornes, S. Aamdal, G. Gaudernack
Journal: Annals of Oncology (2016)
Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils
Authors: Marcos De Lima, Simon Robinson, John McMannis, Amin M Alousi, Rima M Saliba, Mark Munsell, Partow Kebriaei, Chitra Hosing, Simrit Parmar, Laurence Cooper, Nina Shah, Susan Staba Kelly, Gabriela Rondon, Marcelo Fernandez-Vina, Ila Maewall, Doyle Bosque, Catherine M Bollard, Julianne J Chen, Ian K McNiece, Krishna V Komanduri, Yago Nieto, Roy Jones, Borje S Andersson, Uday Popat, Richard E. Champlin, Paul J. Simmons, Elizabeth J. Shpall
Journal: Blood (2010)
Bone Sarcomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 25, pg iii113, 2014)
Authors: J.Y. Blay, A. Bertuzzi, S. Bielack, B. Bjerkehagen, S. Bonvalot, I. Boukovinas, P. Bruzzi, A.P. dei Tos, P. Dileo, M. Eriksson, A. Fedenko, A. Ferrari, S. Ferrari, H. Gelderblom, R.J. Grimer, A. Gronchi, R.L. Haas, K.S. Hall, P. Hohenberger, R. Issels, H. Joensuu, I. Judson, A. le Cesne, S. Litiere, J. Martin-Broto, O. Merimsky, M. Montemurro, C. Morosi, P. Picci, I. Ray-Coquard, P. Reichardt, P. Rutkowski, M. Schlemmer, S. Stacchiotti, V. Torri, A. Trama, F. van Coevorden, D. Vanel, E. Wardelmann, P.G. Casali
Journal: Annals of Oncology (2015)
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients
Authors: A. Destro, C.L.o. Russo, P. Spaggiari, S. Armenia, E. Bellofiore, M. Lorini, T. Brambilla, M.M. Cimino, A. Spinelli, N. Personeni, L. Rimassa, L. Di Tommaso, M. Roncalli
Journal: Annals of Oncology (2016)
Influence of Dihydrofolate Reducatse (DHFR) Gene Polymorphisms on Outcome of Methotrexate Maintenance Therapy in Patients with Acute Lymphoblastic Leukemia
Authors: Dubashi Biswajit, Sunitha Kodidela, Suresh Chandra Pradhan, Debdatta Basu, Ravi Prasad, Umamaheswaran Gurusamy
Journal: Blood (2014)
Report of NCI Ad Hoc Working Group on the Risks Associated With Mammography in Mass Screening for the Detection of Breast Cancer
Authors: Arthur C. Upton, Gilbert W. Beebe, J. Martin Brown, Edith H. Quimby, Claire Shellabarger
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Report of NCI Ad Hoc Working Group on the Risks Associated With Mammography in Mass Screening for the Detection of Breast Cancer Get access Arthur C. Upton, Arthur C. Upton Chairman Search for other works by this author on: Oxford Academic PubMed Google Scholar Gilbert W. Beebe, Gilbert W. Beebe Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Martin Brown, J. Martin Brown Search for other works by this author on: Oxford Academic PubMed Google Scholar Edith H. Quimby, Edith H. Quimby Search for other works by this author on: Oxford Academic PubMed Google Scholar Claire Shellabarger Claire Shellabarger Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 59, Issue 2, August 1977, Pages 480–493, https://doi.org/10.1093/jnci/59.2.479 Published: 01 August 1977
(Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial
Authors: C. Blank, A. van Akkooi, E.A. Rozeman, P. Kvistborg, H.V. van Thienen, B. Stegenga, B. Lamon, J.B.A.G. Haanen, T. Schumacher
Journal: Annals of Oncology (2016)
Differences in eosinophil molecular profiles between children and adults with eosinophilic esophagitis
Authors: C. Lingblom, T. Käppi, H. Bergquist, M. Bove, R. Arkel, R. Saalman, C. Wennerås
Journal: Allergy (2017)

Eosinophilic esophagitis (EoE) afflicts both children and adults. It has been debated whether pediatric EoE and adult EoE represent different disease entities. The objectives of this study were to determine whether the blood eosinophil molecular pattern of children with EoE is (i) distinct from that of healthy children; and (ii) different from that of adults with EoE.Blood eosinophils from children and adults with EoE, and healthy controls, were analyzed with flow cytometry regarding levels of CD23, CD44, CD54, CRTH2, FOXP3, and galectin-10. Eosinophil FOXP3 and galectin-10 mRNA levels were determined by qPCR. The data were analyzed using a multivariate method of pattern recognition.An eosinophil molecular pattern capable of distinguishing children with EoE from control children was identified. A smaller fraction of eosinophils from children with EoE expressed CD44 and a larger fraction expressed CRTH2 than the controls. Eosinophils from children with EoE also had higher levels of galectin-10 mRNA and lower levels of FOXP3 mRNA. The eosinophils from children with EoE had lower levels of surface CD54 and of FOXP3 mRNA compared with the eosinophils from the adult patients. A key finding was the detection in healthy individuals of age-related differences in the levels of several eosinophil markers.Children with EoE can be distinguished from healthy children based on the molecular patterns of their blood eosinophils. Age-related physiologic differences in eosinophil molecular patterns may partly explain the different blood eosinophil phenotypes in children vs adults with EoE.
PDCT-07. HERBY (BO25041): A PHASE II OPEN-LABEL, RANDOMIZED, MULTICENTER, COMPARATIVE STUDY OF BEVACIZUMAB (BEV)-BASED THERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMA (HGG)
Authors: Jacques Grill, Darren Hargrave, Maura Massimino, Eric Bouffet, Amedeo Azizi, Geoffrey McCowage, Adela Cañete, Frank Saran, Marie-Cecile Le Deley, Pascale Varlet, Paul S. Morgan, Tim Jaspan, Chris Jones, Helen Smith, Josep Garcia, Magalie Hilton, Raphael Rousseau, Lauren Abrey, Gilles Vassal
Journal: Neuro-Oncology (2016)

HERBY (BO25041/NCT01390948) aimed to evaluate the efficacy and safety of BEV in addition to standard-of-care therapy ­(radiotherapy [RT]/temozolomide [TMZ]) in pediatric/adolescent patients with newly diagnosed HGG. Patients (≥3–<18 years) had HGG (supratentorial/infratentorial cerebellar/cerebellar peduncular); patients with gliomatosis cerebri or multifocal/metastatic HGGs were excluded. Randomization was stratified by age, surgery, and HGG grade. Diagnosis was confirmed before study entry by central pathology review. Histone status was determined. 121 patients (RT/TMZ n=59; BEV+RT/TMZ n=62; median age 11.0 years; <13 years, n=81; ≥13 years, n=40; 69% grade IV HGG; 50% had a total/near-total resection) were enrolled (October 2011–February 2015; 70 centers [Europe/Australia/Canada]). For RT/TMZ and BEV+RT/TMZ, respectively: 89.8% and 95.2% completed ≥90% of planned RT, and 81.4% and 85.5% completed ≥90% of planned TMZ (concurrent phase); 42.4% and 32.3% completed 12 TMZ cycles in the adjuvant phase. Median duration of survival follow-up: 15.2 months (RT/TMZ) and 16.2 months (BEV+RT/TMZ). Event-free survival (EFS) by central review (primary endpoint) was not significantly different between treatment arms (hazard ratio [HR]=1.44; 95% confidence interval [CI] 0.90–2.30; p=0.13 [log-rank test]). Similar results were observed in subgroup analyses of EFS by age/HGG grade/surgery/HGG location/histone status. Investigator-assessed EFS was also comparable (HR=1.49; 95% CI 0.92–2.40). The 1-year EFS rate was 48% (95% CI 35–61) and 38% (95% CI 26–51) for RT/TMZ versus BEV+RT/TMZ. There was no difference in overall survival (HR=1.23; 95% CI 0.72–2.09; interim assessment). No new safety signals were identified. For RT/TMZ versus BEV+RT/TMZ, respectively: the incidence of grade 3–5 adverse events (AEs) was 68% vs 70%; 0% vs 13% of patients had grade ≥3 proteinuria; 5% vs 22% of patients discontinued treatment due to toxicity (20% discontinued BEV). The addition of BEV to standard-of-care RT/TMZ did not improve EFS (central review) in pediatric patients with newly diagnosed HGG.
Maintenance hormonal therapy (MHT) in metastatic breast cancer (MBC) patients treated with first-line chemotherapy: retrospective analysis of the impact on progression-free survival (PFS) and overall survival (OS) in a “real life” setting
Authors: O. Garrone, M. Di Maio, A.M. Vandone, R. Brizio, P. Vanella, E. Miraglio, A. Comino, M.C. Merlano
Journal: Annals of Oncology (2016)
Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease
Authors: Jieun Uhm, Elizabeth Shin, Fotios V. Michelis, Auro Viswabandya, Jeffrey H. Lipton, Hans A. Messner, Dennis Dong Hwan Kim
Journal: Blood (2015)
TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer
Authors: T.W. Kim, L. Shen, J.M. Xu, V. Sriuranpong, H. Pan, R. Xu, S.-W. Han, T. Liu, Y.S. Park, C. Shir, Y. Bai, F. Bi, J.B. Ahn, S. Qin, Q. Li, C. Wu, F. Zhou, D. Ma, V. Srimuninnimit, J. Li
Journal: Annals of Oncology (2016)
Radiotherapy and cetuximab for elderly patients affected by loco-regionally advanced head and neck cancer
Authors: D. Ferrari, C. Codecà, B. Bocci, F. Crepaldi, C. Careri, M. Blasi, D. Patanè, G. Viale, M. Violati, V. Bordin, S. Caldiera, A. Luciani, S. Zonato, P. Foa
Journal: Annals of Oncology (2016)
Hematite‐Based Photoelectrode Materials for Photoelectrocatalytic Inhibition of Alzheimer's β‐Amyloid Self‐Assembly
Authors: Kayoung Kim, Byung Il Lee, You Jung Chung, Woo Seok Choi, Chan Beum Park
Journal: Advanced Healthcare Materials (2017)

A visible light‐active, hematite‐based photoelectrode platform for suppressing β‐amyloid (Aβ) self‐assembly in vitro is reported. Upon illumination of a light‐emitting diode with an anodic bias, the hematite photoanode generates reactive radical species, such as superoxide ions and hydroxyl radicals, via photoelectrocatalytic process. According to our analyses, the hematite photoanode exhibited a strong inhibitory effect on Aβ aggregation under visible light illumination and anodic bias. We found that hole‐derived radicals played a significant role of oxidizing Aβ peptides, which effectively blocked further aggregation. The efficacy of photoelectrocatalytic inhibition on Aβ aggregation was enhanced by introducing cobalt phosphate (Co‐Pi) as a co‐catalyst on the hematite photoanode, which facilitated the separation of electron‐hole pairs. We verified that both bare and Co‐Pi@hematite photoanodes are biocompatible and effective in reducing Aβ aggregation‐induced cytotoxicity.